Cargando…
Inflammation‐Controlled Anti‐Inflammatory Hydrogels
While autoregulative adaptation is a common feature of living tissues, only a few feedback‐controlled adaptive biomaterials are available so far. This paper herein reports a new polymer hydrogel platform designed to release anti‐inflammatory molecules in response to the inflammatory activation of hu...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982591/ https://www.ncbi.nlm.nih.gov/pubmed/36581490 http://dx.doi.org/10.1002/advs.202206412 |
_version_ | 1784900362615914496 |
---|---|
author | Helmecke, Tina Hahn, Dominik Matzke, Nadine Ferdinand, Lisa Franke, Lars Kühn, Sebastian Fischer, Gunter Werner, Carsten Maitz, Manfred F. |
author_facet | Helmecke, Tina Hahn, Dominik Matzke, Nadine Ferdinand, Lisa Franke, Lars Kühn, Sebastian Fischer, Gunter Werner, Carsten Maitz, Manfred F. |
author_sort | Helmecke, Tina |
collection | PubMed |
description | While autoregulative adaptation is a common feature of living tissues, only a few feedback‐controlled adaptive biomaterials are available so far. This paper herein reports a new polymer hydrogel platform designed to release anti‐inflammatory molecules in response to the inflammatory activation of human blood. In this system, anti‐inflammatory peptide drugs, targeting either the complement cascade, a complement receptor, or cyclophilin A, are conjugated to the hydrogel by a peptide sequence that is cleaved by elastase released from activated granulocytes. As a proof of concept, the adaptive drug delivery from the gel triggered by activated granulocytes and the effect of the released drug on the respective inflammatory pathways are demonstrated. Adjusting the gel functionalization degree is shown to allow for tuning the drug release profiles to effective doses within a micromolar range. Feedback‐controlled delivery of covalently conjugated drugs from a hydrogel matrix is concluded to provide valuable safety features suitable to equip medical devices with highly active anti‐inflammatory agents without suppressing the general immunosurveillance. |
format | Online Article Text |
id | pubmed-9982591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99825912023-03-04 Inflammation‐Controlled Anti‐Inflammatory Hydrogels Helmecke, Tina Hahn, Dominik Matzke, Nadine Ferdinand, Lisa Franke, Lars Kühn, Sebastian Fischer, Gunter Werner, Carsten Maitz, Manfred F. Adv Sci (Weinh) Research Articles While autoregulative adaptation is a common feature of living tissues, only a few feedback‐controlled adaptive biomaterials are available so far. This paper herein reports a new polymer hydrogel platform designed to release anti‐inflammatory molecules in response to the inflammatory activation of human blood. In this system, anti‐inflammatory peptide drugs, targeting either the complement cascade, a complement receptor, or cyclophilin A, are conjugated to the hydrogel by a peptide sequence that is cleaved by elastase released from activated granulocytes. As a proof of concept, the adaptive drug delivery from the gel triggered by activated granulocytes and the effect of the released drug on the respective inflammatory pathways are demonstrated. Adjusting the gel functionalization degree is shown to allow for tuning the drug release profiles to effective doses within a micromolar range. Feedback‐controlled delivery of covalently conjugated drugs from a hydrogel matrix is concluded to provide valuable safety features suitable to equip medical devices with highly active anti‐inflammatory agents without suppressing the general immunosurveillance. John Wiley and Sons Inc. 2022-12-29 /pmc/articles/PMC9982591/ /pubmed/36581490 http://dx.doi.org/10.1002/advs.202206412 Text en © 2022 The Authors. Advanced Science published by Wiley‐VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Helmecke, Tina Hahn, Dominik Matzke, Nadine Ferdinand, Lisa Franke, Lars Kühn, Sebastian Fischer, Gunter Werner, Carsten Maitz, Manfred F. Inflammation‐Controlled Anti‐Inflammatory Hydrogels |
title | Inflammation‐Controlled Anti‐Inflammatory Hydrogels |
title_full | Inflammation‐Controlled Anti‐Inflammatory Hydrogels |
title_fullStr | Inflammation‐Controlled Anti‐Inflammatory Hydrogels |
title_full_unstemmed | Inflammation‐Controlled Anti‐Inflammatory Hydrogels |
title_short | Inflammation‐Controlled Anti‐Inflammatory Hydrogels |
title_sort | inflammation‐controlled anti‐inflammatory hydrogels |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982591/ https://www.ncbi.nlm.nih.gov/pubmed/36581490 http://dx.doi.org/10.1002/advs.202206412 |
work_keys_str_mv | AT helmecketina inflammationcontrolledantiinflammatoryhydrogels AT hahndominik inflammationcontrolledantiinflammatoryhydrogels AT matzkenadine inflammationcontrolledantiinflammatoryhydrogels AT ferdinandlisa inflammationcontrolledantiinflammatoryhydrogels AT frankelars inflammationcontrolledantiinflammatoryhydrogels AT kuhnsebastian inflammationcontrolledantiinflammatoryhydrogels AT fischergunter inflammationcontrolledantiinflammatoryhydrogels AT wernercarsten inflammationcontrolledantiinflammatoryhydrogels AT maitzmanfredf inflammationcontrolledantiinflammatoryhydrogels |